title: PF-04457845
text: # PF-04457845
  
  JZP150 (formerly PF-04457845) is an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an $IC_{50}$ of 7.2nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen.
  
  JZP150 is currently being developed by Jazz Pharmaceuticals and is in a Phase 2 trial in the US for PTSD. Patients will be given 0.3mg orally once per day for up to 12 weeks, or 4.0mg orally once per day for up to 12 weeks, or a placebo.
  
  